GlassScriptPhysician profile
Christina Pecoraro
NPI 1588831325
$4,445.12
in general payments reported to CMS, 2019-2025
26 companies · $979 in 2025
The $979 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $1,081 · 2023: $1,102 · 2024: $855 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $675.03 | 2021-2025 | |
| Abbvie INC. | $462.45 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $428.89 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $399.02 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $376.93 | 2021-2022 | |
| Hologic Sales and Service, LLC | $251.11 | 2023-2025 | Thinprep 2000 Processor |
| Organon LLC | $231.03 | 2021-2025 | Nexplanon |
| Pfizer INC. | $204.55 | 2021-2024 | |
| Evofem Biosciences, INC. | $198.23 | 2022-2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $186.52 | 2024-2025 | Femlyv, Intrarosa |
| Merck Sharp & Dohme LLC | $166.09 | 2022-2025 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $163.51 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Agile Therapeutics, INC. | $119.40 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $77.40 | 2021-2022 | |
| Biogen, INC. | $72.37 | 2024-2025 | Zurzuvae |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $63.76 | 2025 | Veozah |
| Scynexis, INC. | $52.30 | 2022 | |
| Amgen INC. | $49.83 | 2024-2025 | Evenity, Prolia |
| Octapharma USA, INC. | $48.65 | 2024 | Fibryga |
| Shield Therapeutics INC | $46.06 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.51 | 2021-2023 | |
| Lupin INC. | $38.00 | 2021 | |
| Daiichi Sankyo INC. | $27.80 | 2024 | Injectafer |
| Smith+Nephew, INC. | $24.83 | 2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Exact Sciences Corporation | $24.13 | 2024 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $16.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Pecoraro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.